Galera Therapeutics, Inc. (GRTX)
| Market Cap | 2.58M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -19.61M |
| Shares Out | 54.39M |
| EPS (ttm) | -0.36 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 3,700 |
| Average Volume | 432,937 |
| Open | 0.0450 |
| Previous Close | 0.0450 |
| Day's Range | 0.0450 - 0.0450 |
| 52-Week Range | 0.0210 - 0.2900 |
| Beta | 1.83 |
| RSI | 58.68 |
| Earnings Date | Mar 7, 2025 |
About Galera Therapeutics
Galera Therapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapeutics for the transformation of radiotherapy in cancer. The company’s lead product candidate is avasopasem manganese (GC4419), a small molecule dismutase mimetic for the treatment of radiotherapy induced severe oral mucositis in patients with head and neck cancer (HNC); for the treatment of radiotherapy-induced esophagitis in patients with lung cancer; and for patients with HNC undergoing standard-of-care radiotherapy. It also deve... [Read more]
Financial Performance
Financial StatementsNews
Galera Therapeutics completes acquisition of Nova Pharmaceuticals
Galera's development strategy shifts from toxicity reduction to anti-cancer therapeutics, with three trials in patients with highly resistant subsets of advanced breast cancer.
Galera Announces Board Approval of Complete Liquidation and Dissolution
MALVERN, Pa., Aug. 14, 2024 (GLOBE NEWSWIRE) -- Galera Therapeutics, Inc. (Nasdaq: GRTX), a clinical-stage biopharmaceutical company historically focused on developing a pipeline of novel, proprietary...
Galera Reports First Quarter 2024 Financial Results and Recent Corporate Updates
MALVERN, Pa., May 13, 2024 (GLOBE NEWSWIRE) -- Galera Therapeutics, Inc. (Nasdaq: GRTX), a clinical-stage biopharmaceutical company focused on developing a pipeline of novel, proprietary therapeutics ...
Galera Adopts Limited Duration Stockholder Rights Agreement
MALVERN, Pa., May 03, 2024 (GLOBE NEWSWIRE) -- Galera Therapeutics, Inc. (Nasdaq: GRTX), a biopharmaceutical company focused on developing a pipeline of novel, proprietary therapeutics that have the p...
Galera Reports Fourth Quarter and Full Year 2023 Financial Results and Recent Corporate Updates
Company continues to evaluate strategic options to maximize shareholder value Company continues to evaluate strategic options to maximize shareholder value
Galera Reports Third Quarter 2023 Financial Results and Recent Corporate Updates
FDA confirms need for new trial for avasopasem; GRECO trials with rucosopasem to be discontinued Company evaluating potential strategic options to optimize shareholder value MALVERN, Pa., Nov. 14, 202...
Galera Announces Receipt of Type A Meeting Minutes and Strategic Update
FDA confirms need for new trial for avasopasem for severe oral mucositis (SOM) GRECO-2 trial did not pass futility analysis; Company will discontinue both GRECO trials Company reviewing potential stra...
Galera Schedules Type A Meeting with FDA to Discuss Next Steps for Avasopasem
MALVERN, Pa., Sept. 18, 2023 (GLOBE NEWSWIRE) -- Galera Therapeutics, Inc. (Nasdaq: GRTX), a clinical-stage biopharmaceutical company focused on developing and commercializing a pipeline of novel, pro...
Top 5 Health Care Stocks That May Explode In Q3 - BioVie (NASDAQ:BIVI), Galera Therapeutics (NASDAQ:GRTX)
The most oversold stocks in the health care sector presents an opportunity to buy into undervalued companies.
Galera Reports Second Quarter 2023 Financial Results and Recent Corporate Updates
Company received Complete Response Letter from FDA for avasopasem and intends to request Type A meeting with FDA to discuss potential next steps
Galera shares tank after US FDA declines to approve inflammation disease drug
Galera Therapeutics Inc said the U.S. health regulator declined to approve its drug to treat radiotherapy-induced severe mouth inflammation in patients with advanced head and neck cancer undergoing st...
Galera Receives Complete Response Letter from U.S. FDA for Avasopasem Manganese
The Company remains committed to its goal of bringing avasopasem to patients and intends to meet with FDA as soon as possible to discuss potential next steps
Galera Presents Additional Chronic Kidney Disease Data from ROMAN Trial at 2023 ASCO Annual Meeting
As previously reported, avasopasem reduced cisplatin-related chronic kidney disease by 50% compared to placebo at one-year follow-up
Galera Reports First Quarter 2023 Financial Results and Recent Corporate Updates
Avasopasem NDA granted FDA priority review for radiotherapy-induced severe oral mucositis (SOM); PDUFA target date of August 9, 2023
Galera Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
MALVERN, Pa., May 04, 2023 (GLOBE NEWSWIRE) -- Galera Therapeutics, Inc. (Nasdaq: GRTX), a clinical-stage biopharmaceutical company focused on developing and commercializing a pipeline of novel, propr...
Galera Expands Commercial Leadership Team
Company appoints leading sales, market access and operations executives with decades of experience successfully launching and commercializing new oncology products
Galera to Present One-Year Reductions in Cisplatin-Related Chronic Kidney Disease Data from ROMAN Trial at 2023 American Society of Clinical Oncology (ASCO) Annual Meeting
MALVERN, Pa., April 26, 2023 (GLOBE NEWSWIRE) -- Galera Therapeutics, Inc. (Nasdaq: GRTX), a clinical-stage biopharmaceutical company focused on developing and commercializing a pipeline of novel, pro...
Galera Therapeutics: A Possible Solution To Severe Oral Mucositis In Head And Neck Cancer Patients
Galera Therapeutics: A Possible Solution To Severe Oral Mucositis In Head And Neck Cancer Patients.
Galera Announces Presentation of Supplemental Analysis of Phase 3 ROMAN Trial at European Congress on Head and Neck Oncology
MALVERN, Pa., March 10, 2023 (GLOBE NEWSWIRE) -- Galera Therapeutics, Inc. (Nasdaq: GRTX), a clinical-stage biopharmaceutical company focused on developing and commercializing a pipeline of novel, pro...
Galera Reports Fourth Quarter and Full Year 2022 Financial Results and Recent Corporate Updates
Avasopasem NDA granted FDA priority review for radiotherapy-induced severe oral mucositis (SOM); PDUFA target date of August 9, 2023
Galera Therapeutics Announces Pricing of Registered Direct Offering of $30 Million of Common Stock and Warrants
MALVERN, Pa., Feb. 15, 2023 (GLOBE NEWSWIRE) -- Galera Therapeutics, Inc. (Nasdaq: GRTX), a clinical-stage biopharmaceutical company focused on developing and commercializing a pipeline of novel, prop...
Galera Submits New Drug Application for Avasopasem for Severe Oral Mucositis
NDA based on two positive randomized, double-blinded, placebo-controlled trials which enrolled a total of 678 patients NDA based on two positive randomized, double-blinded, placebo-controlled trials w...
Galera to Present at Piper Sandler Annual Healthcare Conference
MALVERN, Pa., Nov. 22, 2022 (GLOBE NEWSWIRE) -- Galera Therapeutics, Inc. (Nasdaq: GRTX), a clinical-stage biopharmaceutical company focused on developing and commercializing a pipeline of novel, prop...
Galera Reports Third Quarter 2022 Financial Results and Recent Corporate Updates
Company on track to submit NDA to U.S. FDA for avasopasem by end of 2022
Galera Announces Presentation of Phase 3 ROMAN Long-term Follow-up Data at 2022 American Society for Radiation Oncology (ASTRO) Annual Meeting
Tumor outcomes and overall survival maintained in patients with HNC at one-year